title: Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension.
abstract: The effects of the red wine polyphenolic compounds (Provinol) on hypertension, left ventricular hypertrophy, myocardial fibrosis, and vascular remodeling were investigated after chronic inhibition of nitric oxide (NO) synthase by administration of N(G)-nitro-L-arginine methyl ester (L-NAME) to rats. Rats were divided into four groups: a control group, a group treated for 4 wk with L-NAME (40 mg x kg(-1) x day(-1)), and two groups treated with L-NAME followed by 3 wk of either spontaneous recovery or recovery with Provinol treatment (40 mg x kg(-1) x day(-1)). Administration of Provinol produced a greater readiness of the decrease in blood pressure than that in the spontaneous recovery group. Provinol significantly depressed myocardial fibrosis and expedited the decrease in aortic cross-sectional area, the increase in endothelium-dependent relaxation, and the decrease in contraction of the aorta. These effects of Provinol were associated with a greater increase of NO synthase activity in the left ventricle and the aorta. The present study provides evidence that Provinol accelerates the regression of blood pressure and improves structural and functional cardiovascular changes produced by chronic inhibition of NO synthesis.
authors.affiliation: Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, 813 71 Bratislava, Slovak Republic.
authors.forename: Iveta
authors.initials: I
authors.lastname: Bernátová
authors.forename: Olga
authors.initials: O
authors.lastname: Pechánová
authors.forename: Pavel
authors.initials: P
authors.lastname: Babál
authors.forename: Sona
authors.initials: S
authors.lastname: Kyselá
authors.forename: Svetoslav
authors.initials: S
authors.lastname: Stvrtina
authors.forename: Ramaroson
authors.initials: R
authors.lastname: Andriantsitohaina
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001011:Aorta / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight; D002320:Cardiovascular Physiological Phenomena; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D066298:In Vitro Techniques; D007930:Leucine / Q000378:metabolism; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D009206:Myocardium / Q000378:metabolism; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D009569:Nitric Oxide / Q000172:deficiency*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology; D009929:Organ Size; D010636:Phenols / Q000627:therapeutic use*; D011108:Polymers / Q000627:therapeutic use*; D059808:Polyphenols; D051381:Rats; D017208:Rats, Wistar; D014920:Wine
chemical_list: D004791:Enzyme Inhibitors; D005419:Flavonoids; D010636:Phenols; D011108:Polymers; D059808:Polyphenols; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D007930:Leucine; D000109:Acetylcholine; D019331:NG-Nitroarginine Methyl Ester; D009638:Norepinephrine